Controlled release composition containing a strontium salt
OwnerChristian Hansen, Henrik Nilsson +2inventors
InventorsChristian Hansen, Henrik Nilsson, Jens Andersen, Stephan Christgau
Life of this patent
Estimating the term…
Abstract
A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.
Claims61
A controlled release pharmaceutical composition for oral use comprising a strontium salt.
A method for treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, the method comprising administering a single daily dose of a controlled release pharmaceutical composition comprising a strontium salt, wherein the amount of strontium salt is adjusted so that the pharmaceutical composition is suitable for administration once daily.
A method for treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a male mammal, the method comprising administering a controlled release pharmaceutical composition comprising a strontium salt, wherein the amount of strontium salt is adjusted so that the pharmaceutical composition is suitable for administration once daily.
21-23. (canceled)
A method for preventing in a subject a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, the method comprising administering a controlled release pharmaceutical composition comprising a strontium salt, wherein the amount of strontium salt is adjusted so that the pharmaceutical composition is suitable for administration once daily.
A method for treating and/or preventing secondary osteoporosis in a subject, the method comprising administering an effective amount of a strontium salt to the subject.
A method for preventing drug induced secondary osteoporosis in a subject, the method comprising administering to the subject a prophylactic amount of a strontium salt before, during or after treatment of the subject with the drug substance that induces secondary osteoporosis.
A pharmaceutical composition comprising a strontium salt and a drug substance that induces osteoporosis together with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.